HUBS Dec 2024 320.000 call
- Yahoo Finance Video
Crypto under pressure, Good Buy or Goodbye: Market Domination
On today's episode of Market Domination, Hosts Julie Hyman and Josh Lipton discuss major market trends from Nvidia's (NVDA) slowdown to Novo Nordisk's (NVO) plans to expand manufacturing capabilities of its GLP-1 weight-loss drugs. As Nvidia continues on its downward trajectory after leading the S&P 500's (^GSPC) growth, B. Riley Wealth Chief Market Strategist Art Hogan believes the market can keep up its momentum without the chip giant: "I think it's a perfect example of a lot of folks being concerned that Nvidia and arguably Nvidia, Microsoft (MSFT), and Apple (AAPL) were such a big part of the 15% that the S&P 500 is higher this year on a year to date basis... But you're seeing basically three or four days where Nvidia has not been leading the charge, and the market's done very well. I think that continues throughout the second half of this year." The European Union has charged Apple under its Digital Markets Act, alleging that the tech giant's App Store practices prevent app developers from directing consumers to cheaper services. TECHnalysis Research President and Chief Analyst Bob O'Donnell believes the investigation is unlikely to conclude anytime soon, and that Apple will have to make some changes: "I do think Apple is going to have to make some tweaks, some things that they don't necessarily want to do, but at the end of the day, again, it's an important enough market that they're going to have to follow some of these requirements that the EU is putting into place. And therefore, long term, I don't think the impact is that big of a deal as far as the value of the company and the way people view the stock." Cryptocurrencies are also under pressure, with bitcoin (BTC-USD) having its worst trading day since March. Meanwhile, the health industry is making major moves, as Altimmune (ALT) reported positive results in Phase 2 trials for its weight-loss drug, a Teladoc Health (TDOC) study showed its AI models contributed to positive growth in diabetes management, and Novo Nordisk revealed plans to invest $4.1 billion in building out a manufacturing facility in Clayton, North Carolina for its GLP-1 weight-loss drugs. This post was written by Melanie Riehl
- Yahoo Finance Video
HubSpot is a stock to invest in, zoom from ZoomInfo: Analyst
Software stocks have been on a tear since generative AI entered the picture. But not all of them will be worthy of your portfolio. In the latest Good Buy or Goodbye, RBC Capital Markets Software Equity Analyst Rishi Jaluria explains why he's long HubSpot (HUBS) but is skipping ZoomInfo (ZI). Jaluria likes HubSpot for a few reasons. He says the company is not only gaining share in the customer relationship management space thanks to its single-platform approach, but that it's seeing success with multi-platform product adoption. Jaluria also thinks HubSpot has "probably one of the most impressive AI roadmaps of any company in front-office application software." Jaluria is skipping ZoomInfo. He says increased competition and increasing macro-pressures are negatives for the stock. He also thinks generative AI and large language models pose a risk to the company. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Stephanie Mikulich.
- Zacks
HubSpot (HUBS) Stock Jumps 3.8%: Will It Continue to Soar?
HubSpot (HUBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
